日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial

溶瘤性H-1细小病毒在首个I/IIa期胶质母细胞瘤试验中显示出安全性和免疫原性活性

Geletneky, Karsten; Hajda, Jacek; Angelova, Assia L; Leuchs, Barbara; Capper, David; Bartsch, Andreas J; Neumann, Jan-Oliver; Schöning, Tilman; Hüsing, Johannes; Beelte, Birgit; Kiprianova, Irina; Roscher, Mandy; Bhat, Rauf; von Deimling, Andreas; Brück, Wolfgang; Just, Alexandra; Frehtman, Veronika; Löbhard, Stephanie; Terletskaia-Ladwig, Elena; Fry, Jeremy; Jochims, Karin; Daniel, Volker; Krebs, Ottheinz; Dahm, Michael; Huber, Bernard; Unterberg, Andreas; Rommelaere, Jean

The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers

溶瘤病毒疗法在癌症治疗中的应用时代:H-1细小病毒治疗血液肿瘤和实体瘤的前景

Angelova, Assia L; Witzens-Harig, Mathias; Galabov, Angel S; Rommelaere, Jean

Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer

溶瘤细小病毒 H-1PV 与吉西他滨在胰腺癌中互补诱导免疫原性细胞死亡

Assia L Angelova, Svitlana P Grekova, Anette Heller, Olga Kuhlmann, Esther Soyka, Thomas Giese, Marc Aprahamian, Gaétan Bour, Sven Rüffer, Celina Cziepluch, Laurent Daeffler, Jean Rommelaere, Jens Werner, Zahari Raykov, Nathalia A Giese

Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies

溶瘤大鼠细小病毒 H-1PV,人类淋巴瘤的治疗候选药物:体外和体内研究

Assia L Angelova, Marc Aprahamian, Ginette Balboni, Henri-Jacques Delecluse, Regina Feederle, Irina Kiprianova, Svitlana P Grekova, Angel S Galabov, Mathias Witzens-Harig, Anthony D Ho, Jean Rommelaere, Zahari Raykov